Please login to the form below

Not currently logged in
Email:
Password:

romosozumab

This page shows the latest romosozumab news and features for those working in and with pharma, biotech and healthcare.

UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe

UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe

With today’s approval of romosozumab we can now offer patients and clinicians a new medicine that can help drive positive changes in secondary fracture prevention.”. ... The first launches of romosozumab in the European Economic Area (EEA) are

Latest news

More from news
Approximately 6 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Investing in the future of R&D Investing in the future of R&D

    One of UCB's brightest prospects is its osteoporosis candidate romosozumab. In January phase II trial results were published that showed significant increases in low bone mineral density at both spine

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    Providing an example, he explains UCB's use of genetics in its development of romosozumab, currently in phase III investigation in partnership with Amgen for use in the treatment of ... UCB's work on romosozumab with Amgen is also an example of the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics